[CAS NO. 18444-66-1] Cucurbitacin E
PRODUCTS SPECIFICATIONS [18444-66-1]
DESCRIPTION [18444-66-1]
Overview
| MDL | MFCD00135936 |
|---|---|
| Molecular Weight | 556.69 |
| Molecular Formula | C32H44O8 |
| SMILES | O[C@H](C1)[C@@]([C@@](C)(O)C(/C=C/C(OC(C)=O)(C)C)=O)([H])[C@](C2)(C)[C@]1(C)[C@]3([H])CC=C4C(C)(C)C(C(O)=C[C@@]4([H])[C@]3(C)C2=O)=O |
3 Publications Citing Use of MCE
Summary
Cucurbitacin E is a natural compound which from Cucurbitaceae plants. Cucurbitacin E significantly suppresses the activity of the cyclin B1 / CDC2 complex.
IC50 & Target
|
cyclin B1/CDC2 |
Autophagy |
In Vitro
To explore the antitumor activity of Cucurbitacin E (CuE) against colorectal cancer (CRC) cells, an in vitro study is initiated in which each of the CRC cell lines is exposed to increasing doses of Cucurbitacin E (0, 2.5, 5, and 7.5 μM) over a period of 24 h. The proliferation of the Cucurbitacin E-treated cancer cells is then measured using the MTT method. Cucurbitacin E is shown to induce morphological changes in the primary colon cancer cells. Microscopic observation showed that following exposure to Cucurbitacin E (5 μM) between 6 and 24 h, the primary colon cancer cells underwent a remarkable change in morphology. Cucurbitacin E inhibits tumor growth by arresting the cell cycle in the G 2 /M phase via GADD45γ gene expression and the blockage of cyclin B1/CDC2 complex in primary CRC cells [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
A high fat diet mice model of metabolic syndrome (HFD-MetS) is developed to assess the role of Cucurbitacin E (CuE) on body weight and fat tissue biology. Significant decrease in body weights of HFD-MetS mice treated with Cucurbitacin E (0.5mg/kg) are found as compared to HFD-MetS mice treated with vehicle alone. Cucurbitacin E treatment reduces all fat pads weights in HFD-MetS mice. 55% reduction is observed in total fat in mice, after treatment with Cucurbitacin E in comparison to HFD-MetS mice. Abdominal obesity is strongly associated with metabolic syndrome. Central obesity is reduced to 50% after Cucurbitacin E treatment as compared to HFD MetS mice, elucidating the effectiveness of Cucurbitacin E in targeting MetS [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Source
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 50 mg/mL ( 89.82 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.7963 mL | 8.9817 mL | 17.9633 mL |
| 5 mM | 0.3593 mL | 1.7963 mL | 3.5927 mL |
| 10 mM | 0.1796 mL | 0.8982 mL | 1.7963 mL |
-
1.
-
2.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (4.49 mM); Clear solution
References
- [1] Hsu YC, et al. Therapeutic ROS targeting of GADD45γ in the induction of G2/M arrest in primary human colorectal cancer cell lines by cucurbitacin E. Cell Death Dis. 2014 Apr 24;5:e1198.
- [2] Murtaza M, et al. Cucurbitacin E reduces obesity and related metabolic dysfunction in mice by targeting JAK-STAT5 signaling pathway. PLoS One. 2017 Jun 9;12(6):e0178910.
Synonyms